Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Moore, Gwen [D-WI-4]

Rep. Moore, Gwen [D-WI-4]

United States · Official source

Records

6,523 records where Rep. Moore, Gwen [D-WI-4] is listed as a sponsor, author, or other actor. Search with topics and years

Resolution· HRESH.Res. 1319 (119th)referred

Ending child poverty.

United States · United States Congress · 21 May 2026

Resolution· HCONRESH.Con.Res. 103 (119th)referred

Directing the President, pursuant to section 5(c) of the War Powers Resolution, to remove United States Armed Forces from hostilities with Iran.

United States · United States Congress · 20 May 2026

This concurrent resolution directs the President to remove U.S. Armed Forces from hostilities against Iran unless explicitly authorized by a declaration of war or a congressional authorization for use of military force against Iran. Elements of the U.S. Armed Forces needed to defend the United States, an ally, or a partner from imminent attack are not covered by this requirement provided the President complies with a specified provision of the War Powers Resolution. (The provision generally requires the President to remove U.S. Armed Forces from hostilities no more than 60 days after the President notifies or is required to notify Congress of such involvement, unless Congress authorizes such use. For more information on the War Powers Resolution, see  CRS In Focus 13134 .)

Bill· HRH.R. 8907 (119th)referred

IMPACT to Save Moms Act

United States · United States Congress · 19 May 2026

Innovative Maternal Payment and Coverage To Save Moms Act or the IMPACT to Save Moms Act This bill requires the Centers for Medicare & Medicaid Services to establish the Perinatal Care Alternative Payment Model Demonstration Project through FY2031 to allow states to test payment models for maternity care, including postpartum care, under Medicaid and the Children's Health Insurance Program (CHIP). 

Bill· HRH.R. 8910 (119th)referred

SLUSH FUND Act of 2026

United States · United States Congress · 19 May 2026

Bill· HRH.R. 8811 (119th)referred

Moms Matter Act

United States · United States Congress · 14 May 2026

Resolution· HRESH.Res. 1285 (119th)referred

Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

United States · United States Congress · 14 May 2026

Bill· HRH.R. 8540 (119th)referred

HCBS Access Act

United States · United States Congress · 28 April 2026

Bill· HRH.R. 8317 (119th)referred

Tech to Save Moms Act

United States · United States Congress · 15 April 2026

Bill· HRH.R. 8235 (119th)referred

Books Save Lives Act

United States · United States Congress · 9 April 2026

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Bill· HRH.R. 8163 (119th)reported

Provider Reimbursement Stability Act of 2026

United States · United States Congress · 30 March 2026

Provider Reimbursement Stability Act of 2026 This bill allows for larger annual adjustments to the Medicare physician fee schedule. It also requires the Centers for Medicare & Medicaid Services (CMS) to make certain corrections to compensate for expenditures under the fee schedule that exceed a certain amount in a given year, and it limits how much certain adjustment factors may vary each year. Current law prohibits annual adjustments to the Medicare physician fee schedule that would result in a more than $20 million difference between the adjusted amount and the non-adjusted amount of total expenditures. The bill increases this threshold to $54.3 million beginning in 2027, with adjustments for inflation every five years beginning in 2032. Additionally, for certain services, the bill requires the CMS to determine the difference between expenditures based on estimated utilization of the service and expenditures based on actual utilization. If this difference exceeds a certain percentage of total expenditures under the fee schedule, the CMS must reconcile this difference by adjusting payments for the following year. This requirement applies to services for which payment was bundled with another service and there was a separate or add-on payment during the previous year. Finally, the CMS must update the prices and rates of each category of direct costs that affect payments (e.g., prices of equipment) at least every five years, with updates made to each category in the same year. The bill also prohibits the CMS from varying a certain adjustment factor by more than 2.5% each year.

Bill· HRH.R. 8074 (119th)referred

Kira Johnson Act

United States · United States Congress · 25 March 2026

Bill· HRH.R. 8080 (119th)referred

Data to Save Moms Act

United States · United States Congress · 25 March 2026

Bill· HRH.R. 8055 (119th)referred

Extending WIC for New Moms Act

United States · United States Congress · 24 March 2026

Extending WIC for New Moms Act This bill amends the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) to extend the eligibility periods for breastfeeding and postpartum women. Specifically, a state program may elect to certify a breastfeeding woman for up to 24 months (currently 1 year) postpartum. The bill also expands the eligibility period for postpartum women to up to 24 months after termination of pregnancy (currently 6 months). The Department of Agriculture must submit a report to Congress evaluating the effect of these changes to the program on (1) maternal and infant health outcomes, (2) breastfeeding rates, and (3) qualitative evaluations of family experiences under WIC. 

Bill· HRH.R. 7995 (119th)open

CONNECT Act

United States · United States Congress · 19 March 2026

Bill· HRH.R. 7973 (119th)referred

Momnibus Act

United States · United States Congress · 18 March 2026